Thalomid Market Worldwide Industry Analysis, Future Demand and Forecast till 2028

 

The global Thalomid market is expected to grow at a moderate CAGR during the forecast period (2022-2028). Thalidomide was discovered to be extremely effective in suppressing erythema nodosum leprosum (ENL). Thalomid (thalidomide) capsules have been approved by the US Food and Drug Administration (FDA) for the acute treatment of the cutaneous manifestations of moderate to severe ENL. Thalidomide is currently being studied for the treatment of a wide range of diseases, including conditions thought to have an inflammatory or immune basis, cancer, and HIV-related complications. Off-label use of prescription thalidomide has resulted from interest in the potential anti-inflammatory, immunomodulatory, and anti-angiogenic effects of thalidomide.

Some of the key players profiled in the study are Celgene Corp. (Bristol-Myers Squibb Co.)

Thalomid Market Segmentation:

By Type 

• 50mg
• 100mg
• 200mg

By Application 

• Retail Pharmacy
• Hospital Pharmacy
• Others

Geographic Coverage

• North America Market Size and/or Volume
• Latin America Market Size and/or Volume
• Europe Market Size and/or Volume
• Asia-Pacific Market Size and/or Volume
• Rest of the world Market Size and/or Volume

Key questions answered in this report:

• What is the size of the Thalomid market and what is its expected growth rate?
• What are the primary driving factors that push the Thalomid Market forward?
• What are the Thalomid Industry’s top companies?
• What are the different categories that the Thalomid Market caters to?
• What will be the fastest-growing segment or region?
• In the value chain, what role do essential players play?
• What is the procedure for getting a free copy of the Thalomid Market sample report and company profiles?